Cargando…
Frontiers in Anti-Infective Drug Discovery
This book series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the book series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Singapore :
Bentham Science Publishers,
2020.
|
| Colección: | Frontiers in Anti-Infective Drug Discovery Ser.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Mu 4500 | ||
|---|---|---|---|
| 001 | EBSCO_on1206399727 | ||
| 003 | OCoLC | ||
| 005 | 20231017213018.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 201114s2020 si o ||| 0 eng d | ||
| 040 | |a EBLCP |b eng |c EBLCP |d YDX |d EBLCP |d N$T |d OCLCF |d OCLCO |d K6U |d OCLCQ |d OCLCO | ||
| 019 | |a 1200198500 | ||
| 020 | |a 9811412383 | ||
| 020 | |a 9789811412387 |q (electronic bk.) | ||
| 035 | |a (OCoLC)1206399727 |z (OCoLC)1200198500 | ||
| 050 | 4 | |a RM267 | |
| 082 | 0 | 4 | |a 616.9/0461 |2 23 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Atta-ur-Rahman. | |
| 245 | 1 | 0 | |a Frontiers in Anti-Infective Drug Discovery |h [electronic resource]. |
| 260 | |a Singapore : |b Bentham Science Publishers, |c 2020. | ||
| 300 | |a 1 online resource (277 p.). | ||
| 490 | 1 | |a Frontiers in Anti-Infective Drug Discovery Ser. | |
| 500 | |a Description based upon print version of record. | ||
| 520 | |a This book series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the book series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for dev. | ||
| 505 | 0 | |a Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- Eradication of Helicobacter pylori Infection with Non-Bismuth Quadruple Concomitant Therapy -- Javier P. Gisbert* and Adrian G. McNicholl -- INTRODUCTION -- OBJECTIVE -- BIBLIOGRAPHICAL SEARCHES -- EFFICACY OF THE CONCOMITANT REGIMEN -- COMPARISON BETWEEN CONCOMITANT AND STANDARD TRIPLE REGIMEN -- COMPARISON BETWEEN CONCOMITANT AND SEQUENTIAL REGIMENS -- EFFECTS OF DIFFERENT VARIABLES ON THE EFFICACY OF CONCOMITANT THERAPY -- Clarithromycin Resistance -- Nitroimidazole Resistance | |
| 505 | 8 | |a Dual Clarithromycin and Metronidazole Resistance -- Duration of Treatment -- HOW COULD WE EVEN INCREASE THE EFFICACY OF THE CONCOMITANT TREATMENT? -- WHAT ARE THE RESULTS WITH THE CONCOMITANT TREATMENT IN CLINICAL PRACTICE? THE EXPERIENCE OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT -- CONCLUSIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Drug Discovery Strategies Against Emerging Coronaviruses: A Global Threat | |
| 505 | 8 | |a Paulo Fernando da Silva Santos-Júnior1, Igor José dos Santos Nascimento1, Thiago Mendonça de Aquino1, João Xavier de Araújo-Júnior2 and Edeildo Ferreira da Silva-Júnior1,2,* -- INTRODUCTION -- BIOLOGICAL ASPECTS, SIGNS/SYMPTOMS AND DIAGNOSIS FOR MERS-COV, SARS-COV, AND SARS-COV-2 -- STRATEGIES USED FOR DISCOVERING NEW POTENTIAL DRUGS -- Natural Source -- Classical Methods Applied for Discovering New Antiviral Agents -- Virtual Screening and Computational Techniques for Designing New Antiviral Agents -- Drug Repurposing -- High-Throughput Screening (HTS) for Discovering New Antiviral Agents | |
| 505 | 8 | |a Case Study 4: Mycobacterium Tuberculosis (Mtb) -- Pantothenate Synthetase (PanC) -- Mtb Transcriptional Repressor (EthR) -- Mycocyclosin Synthase (CYP121) -- Fructose 1,6-bisphosphate Aldolase (FBA) -- RECENT ADVANCES IN FBDD -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Phage Therapy as a Tool for Control of Foodborne Diseases: Advantages and Limitations -- S. Pacios-Michelena1,2, R. Rodríguez-Herrera1, A. C. Flores-Gallegos1, M.L Chávez González2, E.P. Segura-Ceniceros2, R. Ramos-González3 and A. Ilyina2,* -- INTRODUCTION -- BACTERIOPHAGE | |
| 590 | |a eBooks on EBSCOhost |b EBSCO eBook Subscription Academic Collection - Worldwide | ||
| 650 | 0 | |a Anti-infective agents. | |
| 650 | 0 | |a Communicable diseases. | |
| 650 | 2 | |a Anti-Infective Agents | |
| 650 | 2 | |a Communicable Diseases | |
| 650 | 6 | |a Antiinfectieux. | |
| 650 | 6 | |a Maladies infectieuses. | |
| 650 | 7 | |a Anti-infective agents |2 fast | |
| 650 | 7 | |a Communicable diseases |2 fast | |
| 700 | 1 | |a Choudhary, M. Iqbal. | |
| 776 | 0 | 8 | |i Print version: |a Atta-ur-Rahman |t Frontiers in Anti-Infective Drug Discovery: Volume 8 |d Singapore : Bentham Science Publishers,c2020 |z 9789811412370 |
| 830 | 0 | |a Frontiers in Anti-Infective Drug Discovery Ser. | |
| 856 | 4 | 0 | |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2649044 |z Texto completo |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL6388636 | ||
| 938 | |a YBP Library Services |b YANK |n 301624541 | ||
| 938 | |a EBSCOhost |b EBSC |n 2649044 | ||
| 994 | |a 92 |b IZTAP | ||